Compare Howmet Aerospace Inc (HWM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Moderna, Inc. — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Howmet Aerospace Inc and Moderna, Inc. are close in size by market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Moderna, Inc. for 59 Days on average.
| HWM | MRNA | |
|---|---|---|
Market Cap | $88.76B | $78.65B |
Volume | 2,648,516 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $292.65 | $203.46 |
52-Week Low | $184.09 | $22.36 |
Typical Hold Time | 35 Days | 59 Days |
Enterprise Value | $92.86B | $74.80B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $222.53, down 0.08% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with revenue and earnings growth, a net income margin of 20.52%, and consistent quarterly EPS beats. Analyst consensus is overwhelmingly bullish with a $328.10 price target, supported by positive news on defense and aerospace demand.
The outlook for HWM is positive due to robust financial performance and sector tailwinds, but risks include technical weakness and competitive pressures. Investment opportunity lies in its growth trajectory and shareholder returns, though investors should monitor execution risks and market volatility.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
